| Cas No.: | 18422-05-4 |
| SMILES: | O.OP(OC[C@H]1O[C@@H](N2C=NC3=C(N=CN=C23)N)[C@H](O)[C@@H]1O)(O)=O |
| Formula: | C10H14N5O7P.H2O |
| M.Wt: | 365.24 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | In Vitro Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist[1]. Adenosine 5'-monophosphate monohydrate (5′-AMP)-induced cell toxicity is negligible at concentrations of 25 to 400 μM in RAW264.7 cells. Adenosine 5'-monophosphate monohydrate significantly attenuates the mRNA expression of tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 in RAW264.7 cells. The dose-dependence of TNF-α and IL-6 mRNA show that at concentration of 400 μM, Adenosine 5'-monophosphate monohydrate exhibits the maximum inhibition. Exposure of cells to Adenosine 5'-monophosphate monohydrate significantly reduces recruitment of NF-κB p65 to TNF-α, IL-6, and IL-1β gene promoters. In Vivo C57BL/6J mice treated with Adenosine 5'-monophosphate monohydrate (5′-AMP) markedly increases hepatic adenosine level. Survival rate in PBS-treated mice (n=15) is 60% (8 h) and 33.3% (24 h), whereas survival rate in Adenosine 5'-monophosphate monohydrate-treated mice (n=15) is 100% (8 h) and 93.3% (24 h). Serum aspartate transaminase (AST) and alanine transaminase (ALT) levels are significantly lowered in the Adenosine 5'-monophosphate monohydrate group than in the vehicle group. The area and extent of necrosis is attenuated and the infiltration of inflammatory cells is reduced in the Adenosine 5'-monophosphate monohydrate group. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
